Latest data with ONO-4059 and ibrutinib in CLL and mantle cell lymphoma

Prof. Simon Rule from Plymouth Hospital, UK, discusses data presented at EHA19 on the second-generation oral BTK inhibitor, ONO-4059. One study presented relates to CLL; the other to non-Hodgkins lymphoma (NHL). In both studies, ONO-4059 shows promising results that might allow it to compete with ibrutinib. He also outlines the benefits seen with ibrutinib in several haematological cancers, and a poster showing two-year ibrutinib toxicity data.